In the safety run-in phase, 6 patients were enrolled, and the primary end point of that part was safety. In the expansion part, 34 patients will be enrolled. The primary end point of the expansion ...

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without detectable cancer for years after facing certain death. By Gina Kolata A ...

Johnson & Johnson’s (J&J’s) multiple myeloma combination of Tecvayli (teclistamab-cqyv) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) as an induction treatment has elicited a 100% overall ...